Advertisement

Topics

LYSOGENE Company Profile

14:33 EST 14th December 2018 | BioPortfolio

LYSOGENE is a clinical stage biotechnology company committed to the development and commercialization of innovative therapies for patients affected with rare disorders and high unmet medical needs. LYSOGENE’s team translated its rAAVrh10 lead product for Sanfilippo from bench to bedside in an unprecedented fashion over the last years. Its lead product is for Sanfilippo syndrome, a neurodegenerative lysosomal storage disorder considered to be a perfect model for gene therapy. LYSOGENE is currently expanding its pipeline to additional diseases with high unmet medical needs. Lysogene was launched in 2009. It completed a Series A financing in May 2014 with leading life sciences investors Sofinnova Partners, BPI Innobio and Novo AIS.


News Articles [14 Associated News Articles listed on BioPortfolio]

Sarepta Acquires U.S., ex-European Rights to Lysogene MPS III Gene Therapy Candidate LYS-SAF302

Sarepta Therapeutics has acquired U.S. and other ex-European rights to Lysogene’s Phase II/III-bound Mucopolysaccharidosis type IIIA (MPS IIIA) gene therapy candidate LYS-SAF302, through a licensing...

Sarepta gains ex-European license to Lysogene's LYS-SAF302 MPS IIIA gene therapy candidate

Sarepta Therapeutics Inc. licensed exclusive worldwide commercialization (except in Europe) and manufacturing rights to Lysogene's LYS-SAF302 gene therapy candidate for the lysosomal storage disorder ...

Sarepta gets gene therapy candidate, Lysogene extends runway

Lysogene Announces Upcoming Presentations at the 2018 International MPS symposium

CAMBRIDGE, Mass. and PARIS, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Lysogene (FR0013233475 – LYS), a pioneering biopharmaceutical company specializing in gene therapy targeting central nervous system (...

Lysogene Reports Second Quarter Cash Position and Provides Business and Strategic Update

CAMBRIDGE, Mass. and PARIS, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Lysogene (FR0013233475 – LYS), a pioneering biopharmaceutical company specializing in gene therapy targeting central nervous system (...

. @Sarepta Acquires U.S., ex-European Rights to @LYSOGENE MPS III Gene Therapy Candidate LYS-SAF302: http://ow.ly/qUCu30meMnb pic.twitter.com/UAcEzd55Mn

. @Sarepta Acquires U.S., ex-European Rights to @LYSOGENE MPS III Gene Therapy Candidate LYS-SAF302: http://ow.ly/qUCu30meMnb  pic.twitter.com/UAcEzd55Mn

On eve of pivotal Phase II/III trial, @LYSOGENE MPS III #genetherapy candidate LYS-SAF302 rights outside Europe acquired by @Sarepta : http://ow.ly/qUCu30meMnb 

On eve of pivotal Phase II/III trial, @LYSOGENE MPS III #genetherapy candidate LYS-SAF302 rights outside Europe acquired by @Sarepta : http://ow.ly/qUCu30meMnb 

. @Sarepta Acquires U.S., ex-European Rights to @LYSOGENE MPS III Gene Therapy Candidate LYS-SAF302: http://ow.ly/qUCu30meMnb pic.twitter.com/zatjs2W0db

. @Sarepta Acquires U.S., ex-European Rights to @LYSOGENE MPS III Gene Therapy Candidate LYS-SAF302: http://ow.ly/qUCu30meMnb  pic.twitter.com/zatjs2W0db

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

LYSOGENE

LYSOGENE is a clinical stage biotechnology company committed to the development and commercialization of innovative therapies for patients affected with rare disorders and high un...

More Information about "LYSOGENE" on BioPortfolio

We have published hundreds of LYSOGENE news stories on BioPortfolio along with dozens of LYSOGENE Clinical Trials and PubMed Articles about LYSOGENE for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of LYSOGENE Companies in our database. You can also find out about relevant LYSOGENE Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...


Corporate Database Quicklinks



Searches Linking to this Company Record